BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9690313)

  • 1. [Biological perspectives].
    Pujol JL; Demoly P; Quantin X; Simony J; Parrat E; Lehmann M; Daurès JP; Jolimoy G; Grenier J; Pau B; Godard P
    Rev Mal Respir; 1998 Jun; 15(3 Pt 2):428-40. PubMed ID: 9690313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oncogenes, differentiation markers and morphological criteria as prognostic parameters in non-small-cell bronchial carcinoma].
    Thomas M; Junker K
    Dtsch Med Wochenschr; 1997 Oct; 122(43):1327-31. PubMed ID: 9410698
    [No Abstract]   [Full Text] [Related]  

  • 4. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers.
    Tammemagi MC; McLaughlin JR; Bull SB
    Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):625-34. PubMed ID: 10428201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.
    Choma D; Daurès JP; Quantin X; Pujol JL
    Br J Cancer; 2001 Jul; 85(1):14-22. PubMed ID: 11437396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of E-cadherin and nm23 is associated with the clinicopathological factors of human non-small cell lung cancer in China.
    Chen XF; Zhang HT; Qi QY; Sun MM; Tao LY
    Lung Cancer; 2005 Apr; 48(1):69-76. PubMed ID: 15777972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
    Bréchot JM; Molina T; Theobald S; Depierre A; Lagrange JL; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Lemarié E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stcebner-Delbarre A;
    Bull Cancer; 2002 Oct; 89(10):857-67. PubMed ID: 12441277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
    Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N
    Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent polymorphic variations but rare tumour specific mutations of the S100A2 on 1q21 in non-small cell lung cancer.
    Strazisar M; Rott T; Glavac D
    Lung Cancer; 2009 Mar; 63(3):354-9. PubMed ID: 18656279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of features of human lung cancer cell lines and their corresponding tumors.
    Wistuba II; Bryant D; Behrens C; Milchgrub S; Virmani AK; Ashfaq R; Minna JD; Gazdar AF
    Clin Cancer Res; 1999 May; 5(5):991-1000. PubMed ID: 10353731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
    Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
    Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centrosome abnormalities in non-small cell lung cancer: correlations with DNA aneuploidy and expression of cell cycle regulatory proteins.
    Jung CK; Jung JH; Lee KY; Kang CS; Kim M; Ko YH; Oh CS
    Pathol Res Pract; 2007; 203(12):839-47. PubMed ID: 17913384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance.
    Hayashi M; Tokuchi Y; Hashimoto T; Hayashi S; Nishida K; Ishikawa Y; Nakagawa K; Tsuchiya S; Okumura S; Tsuchiya E
    Anticancer Res; 2001; 21(1B):535-40. PubMed ID: 11299800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.